Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers of BRCA1/2 Pathogenic Variants.

International journal of molecular sciences - 28 May 2024

Huber Deborah, Hatzipanagiotou Maria, Schüler-Toprak Susanne, Ortmann Olaf, Treeck Oliver

Abstract excerpt

There is evidence suggesting that endocrine interventions such as hormone replacement therapy and hormonal contraception can increase breast cancer (BC) risk. Sexual steroid hormones like estrogens have long been known for their adverse effects on BC development and progression via binding to estrogen receptor (ER) α. Thus, in recent years, endocrine interventions that include estrogens have been discussed more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Estrogen Receptor alpha

Share to Genetic Predisposition to Disease

Share to Heterozygote

Share to Mutation

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 38892081
DOI: 10.3390/ijms25115894
PMCID: PMC11172552

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers of BRCA1/2 Pathogenic Variants.PMID 38892081Read ↗

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.Semantic proximity Read ↗

BRCA1/2 carriers and endocrine risk modifiers.Semantic proximity Read ↗

Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.Semantic proximity Read ↗

A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.Semantic proximity Read ↗

Estrogen receptor variants in breast cancer.Semantic proximity Read ↗

Pushing estrogen receptor around in breast cancerSemantic proximity Read ↗

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.Semantic proximity Read ↗

The role of estrogens in BRCA1/2 mutation carriers: reflections on the past, issues for the future.Semantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

Estrogen receptors (ER<sub>α</sub>versus ER<sub>β</sub>): friends or foes in human biology?Semantic proximity Read ↗

The Effects of Sex Protein Receptors and Sex Steroid Hormone Gene Polymorphisms on Breast Cancer Risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.